A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Dinesh,Khanna

第一单位： Department of Internal Medicine, University of Michigan Scleroderma Clinic, Ann Arbor, MI, USA.

作者： Dinesh,Khanna ^[1] ; Jeska,de Vries-Bouwstra ^[2] ; Anna-Maria,Hoffmann-Vold ^[3] ; Masataka,Kuwana ^[4] ; Andrea Hsiu Ling,Low ^[5] ; Susanna,Proudman ^[6] ; Mary,Flack ^[7] ; Anjli,Kukreja ^[8] ; Nora,Fagan ^[9] ; Oliver,Distler ^[10]

作者单位： Department of Internal Medicine, University of Michigan Scleroderma Clinic, Ann Arbor, MI, USA. ^[1] Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. ^[2] Department of Rheumatology, Oslo University Hospital, Oslo, Norway.;Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. ^[3] Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. ^[4] Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.;Duke-National University of Singapore Medical School, Singapore. ^[5] Discipline of Medicine, University of Adelaide and Rheumatology Unit, Royal Adelaide Hospital, Adelaide, SA, Australia. ^[6] TA Inflammation Medicine, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. ^[7] Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. ^[8] Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. ^[9] Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. ^[10]

关键词 SSc clinical trial fibrosis microvasculopathy sGC activator

DOI 10.1177/23971983241291923

PMID 39544899

发布时间 2024-11-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of scleroderma and related disorders

23971983241291923页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.

Journal of scleroderma and related disorders

相似文献

Journal of scleroderma and related disorders

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.

Journal of scleroderma and related disorders

相似文献

Journal of scleroderma and related disorders

相关期刊

检索历史清除